A Study to Investigate the Effect of Urine Acid-base Disequilibrium on the Pharmacokinetics of Captopril

NCT ID: NCT06292091

Last Updated: 2025-05-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-02-28
• Study Completion Date: 2024-04-01

Brief Summary

The aim of this study is to evaluate the effect of urine acid-base disequilibrium on the pharmacokinetics of captopril in healthy male volunteers.

Detailed Description

• Pharmacokinetic analysis of captopril before and after urine acid-base imbalance
• Safety analysis

Conditions

Hypertension

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Captopril

Single dose of captopril 12.5 mg

Group Type: ACTIVE_COMPARATOR

Captopril 12.5 Mg

Intervention Type: DRUG

12.5 mg of captopril

Sodium bicarbonate+captopril

Single dose of captopril 12.5 mg during multiple doses of sodium bicarbonate 1 g every 4-6 hours

Group Type: EXPERIMENTAL

Captopril 12.5 Mg

Intervention Type: DRUG

12.5 mg of captopril

Sodium bicarbonate 4 G

Intervention Type: DRUG

4 g of sodium bicarbonate

Torsemide+captopril

Single dose of captopril 12.5 mg during multiple doses of torsemide 20 mg every 6-12 hours

Group Type: EXPERIMENTAL

Captopril 12.5 Mg

Intervention Type: DRUG

12.5 mg of captopril

Torsemide 20 MG

Intervention Type: DRUG

20 mg of torsemide

Interventions

Captopril 12.5 Mg

12.5 mg of captopril

Intervention Type: DRUG

Sodium bicarbonate 4 G

4 g of sodium bicarbonate

Intervention Type: DRUG

Torsemide 20 MG

20 mg of torsemide

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy male volunteer aged 19 to 50 years at screening
• Body weight between 50.0 kg and 90.0 kg and body mass index (BMI) between 18.5 kg/m2 and 29.9 kg/m2 at screening

• Body Mass Index (kg/m2) = Weight (kg)/{Height (m)}2
• Participants who voluntarily decided to participate and agreed in writing to comply with study instructions after receiving sufficient explanation and complete understanding of the study
• Participants who are suitable as test subjects for this test as determined by the investigator through physical examination, clinical laboratory tests, and interviews, etc.

Exclusion Criteria

• Participants who have or have a history of clinically significant hepatobiliary system (severe liver failure, viral hepatitis, etc.), kidney (severe renal impairment, etc.), nervous system, immune system, respiratory system, digestive system, endocrine system, blood/tumor, cardiovascular system (heart failure, Torsades de pointes, etc.), urinary system, mental system (mood disorder, obsessive-compulsive disorder, etc.), and sexual dysfunction, etc.
• Evidence or past history of gastrointestinal disease (Crohn's disease, gastrointestinal ulcer, gastritis, gastroesophageal reflux disease, etc.) or past history of gastrointestinal surgery (except for simple appendectomy and hernia repair) that might affect the safety and PK assessment of the investigational product.
• Hypersensitivity to drugs including captopril, sodium bicarbonate, and torsemide or other drugs (aspirin, antibiotics, etc.) or history of clinically significant hypersensitivity reactions
• Participants with genetic problems such as lactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
• Positive serum test (HBs antigen, HCV antibody, HIV antigen-antibody, and RPR) at screening
• Past history of alcohol and drug abuse or a positive urine test for drugs with abuse potential at screening
• Any abnormalities in vital signs after 3 minutes rest at screening

• Systolic blood pressure < 90 mmHg or > 150 mmHg, Diastolic blood pressure < 60 mmHg or > 100 mHg
• QT/QTcF > 450 msec or any abnormalities on electrocardiogram (ECG) at screening
• Any abnormalities in blood tests at screening

• AST (SGOT), ALT (SGPT) > 60 IU/L, creatinine clearance (CKD-EPI equation) < 80 mL/min
• Past or planned treatment with any prescription drugs or herbal medicine within 2 weeks, or any over the counter drugs, health functional foods, or vitamin supplements within 1 week, prior to the first scheduled dose (individual who is eligible based on other criteria may participate in the study at the discretion of the investigator).
• Participants who have taken drugs that induce drug-metabolizing enzymes such as barbiturates or inhibit drug metabolism such as clarithromycin within 1 month prior to the first scheduled dose
• Treatment with any investigational product in another clinical trial within 6 months prior to the first scheduled dose

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Seoul National University Hospital

OTHER

Sponsor Role: lead

Responsible Party

SeungHwan Lee

Associate Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Seoul National University Hospital

Seoul, Seoul, South Korea

Countries

South Korea

Other Identifiers

Ur_ABD_PK

Identifier Type: -

Identifier Source: org_study_id